24 September 2015  
EMA/CHMP/568489/2015  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Eylea 
aflibercept 
On 24 September 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Eylea. The marketing authorisation holder for this medicinal product is Bayer Pharma AG. 
The CHMP adopted a new indication as follows: 
treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV). 
For information, the full indication for Eylea will be as follows2: 
“Eylea is indicated for adults for the treatment of 
•  neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), 
• 
• 
visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or 
central RVO) (see section 5.1), 
visual impairment due to diabetic macular oedema (DME) (see section 5.1), 
•  visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see 
section 5.1).” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
